In a notable movement within the healthcare services sector, Berkshire Hathaway Inc. and its controlling shareholder, Warren E. Buffett, have reported a major sale of DaVita Inc. (NASDAQ:DVA) common stock. According to recent disclosures, the transaction took place on May 1, 2026, involving the liquidation of 1,220,376 shares. The shares were sold at a price point of $149.8429 per share, resulting in total proceeds of roughly $182.8 million.
Following this reduction in position, the combined holdings of Berkshire Hathaway and Mr. Buffett in DaVita common stock stand at 28,880,209 shares. While the recent sale occurred, DaVita's market valuation has seen upward movement; the stock recently climbed to $157.04, positioning it near its 52-week high of $159.42. This reflects a broader trend for the company, as shares have appreciated by approximately 30% over the preceding six months.
Ownership Structure and Beneficial Interests
The reporting details regarding these holdings involve various indirect ownership structures. Of the total shares held, 13,906,601 are owned by Government Employees Insurance Company (GEICO), which operates as a subsidiary of Berkshire Hathaway. Consequently, Berkshire may be viewed as having a beneficial ownership and pecuniary interest in these specific shares. As the controlling stockholder of Berkshire, Mr. Buffett may also be deemed to have a beneficial ownership interest to the extent of his pecuniary interest, though he has formally disclaimed beneficial ownership outside of that interest.
Furthermore, an additional 14,973,608 shares are held through various pension plans associated with Berkshire's subsidiaries. These include the BNSF Master Retirement Trust and the Berkshire Hathaway Inc. Consolidated Pension Plan. In relation to these specific pension plan holdings, Berkshire, Mr. Buffett, and the respective pension plans have disclaimed beneficial ownership.
Financial Performance and Valuation Context
The divestment comes on the heels of a strong fiscal period for DaVita HealthCare Partners Inc. The company's first-quarter 2026 financial results exceeded market expectations across several key metrics. Specifically, DaVita reported earnings per share (EPS) of $2.87, which outperformed the anticipated $2.32. Revenue for the quarter also arrived ahead of forecasts, totaling $3.42 billion against a projected $3.34 billion.
Despite these robust quarterly results, the company's stock faced downward pressure in aftermarket trading. This movement is attributed to broader market volatility and specific challenges currently facing the healthcare sector. From a valuation perspective, InvestingPro analysis suggests that DaVita appears undervalued based on Fair Value estimates. The company currently trades at a P/E ratio of 16.4 with a total market capitalization of $10.3 billion.
Market Analysis Summary
Key Points:
- Significant Divestment: Berkshire Hathaway and Warren Buffett sold over 1.2 million shares of DVA, totaling $182.8 million in value.
- Strong Fundamentals: DaVita reported Q1 2026 earnings and revenue that both beat analyst forecasts.
- Positive Price Momentum: Despite the sale, DVA shares have risen about 30% over the last half-year and are trading near their annual highs.
These developments impact the healthcare services sector and broader equity markets by signaling shifts in institutional positioning even amidst strong fundamental performance.
Risks and Uncertainties:
- Sector-Specific Volatility: The company has experienced stock declines in aftermarket sessions due to challenges within its specific industry sector.
- Macroeconomic Pressure: Broader market volatility continues to influence the price action of healthcare stocks like DaVita.
These uncertainties affect the stability of healthcare-focused investment portfolios and can lead to sudden shifts in valuation despite positive earnings reports.